Argita D Salindri1,2, Rose-Marie F Sales2, Lauren DiMiceli2, Marcos C Schechter3, Russell R Kempker3, Matthew J Magee1. 1. 1 Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia. 2. 2 Tuberculosis Program, Division of Health Protection, Georgia Department of Public Health, Atlanta, Georgia; and. 3. 3 Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Abstract
RATIONALE: Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear. OBJECTIVES: This study aims to understand 1) factors associated with INH-monoresistant TB and 2) the association between INH monoresistance and response to TB treatment. METHODS: We studied all patients with TB (age, ≥15 yr) reported to the Georgia State Electronic Notifiable Disease Surveillance System (SENDSS) from 2009 to 2014. INH-monoresistant TB was defined as a Mycobacterium tuberculosis isolate resistant to isoniazid only. Time to sputum culture conversion was defined as the time (measured in days) from TB treatment initiation to the date of the first consistently negative culture result reported to the SENDSS. Logistic regression and Cox proportional hazard models were used to estimate the odds and hazard rate of sputum culture conversion, all-cause mortality, and poor TB outcome among patients with INH-monoresistant TB. RESULTS: Among 1,141 culture-confirmed patients with available drug susceptibility testing results, 998 (87.5%) were susceptible to TB first-line drugs, and 143 (12.5%) were patients with INH-monoresistant TB. In multivariable analysis, male sex (adjusted odds ratio [aOR], 1.62; 95% confidence interval [CI], 1.01-2.67) and homelessness (aOR, 5.55; 95% CI, 3.38-9.17) were associated with higher odds of INH-monoresistant TB. In the same multivariable model, older age (≥65 yr old) (aOR, 0.21; 95% CI, 0.07-0.55) and miliary disease (aOR, 0.19; 95% CI, 0.01-0.96) were associated with lower odds of INH-monoresistant TB. Among 1,116 patients with pulmonary TB, the median time to sputum culture conversion was 30 days (interquartile range, 13-58). The rate of culture conversion was similar among patients with and without INH monoresistance (adjusted cause-specific hazard ratio, 1.15; 95% CI, 0.95-1.40). INH-monoresistant TB was not significantly associated with poor TB treatment outcomes (aOR, 1.61; 95% CI, 0.67-3.70) or mortality during TB treatment (aOR, 1.72; 95% CI, 0.58-4.94). CONCLUSIONS: Our findings suggest that compared with drug-susceptible TB, patients in Georgia with INH-monoresistant TB have a similar response to TB treatment including culture conversion rate, final TB treatment outcome, and all-cause mortality.
RATIONALE: Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear. OBJECTIVES: This study aims to understand 1) factors associated with INH-monoresistant TB and 2) the association between INH monoresistance and response to TB treatment. METHODS: We studied all patients with TB (age, ≥15 yr) reported to the Georgia State Electronic Notifiable Disease Surveillance System (SENDSS) from 2009 to 2014. INH-monoresistant TB was defined as a Mycobacterium tuberculosis isolate resistant to isoniazid only. Time to sputum culture conversion was defined as the time (measured in days) from TB treatment initiation to the date of the first consistently negative culture result reported to the SENDSS. Logistic regression and Cox proportional hazard models were used to estimate the odds and hazard rate of sputum culture conversion, all-cause mortality, and poor TB outcome among patients with INH-monoresistant TB. RESULTS: Among 1,141 culture-confirmed patients with available drug susceptibility testing results, 998 (87.5%) were susceptible to TB first-line drugs, and 143 (12.5%) were patients with INH-monoresistant TB. In multivariable analysis, male sex (adjusted odds ratio [aOR], 1.62; 95% confidence interval [CI], 1.01-2.67) and homelessness (aOR, 5.55; 95% CI, 3.38-9.17) were associated with higher odds of INH-monoresistant TB. In the same multivariable model, older age (≥65 yr old) (aOR, 0.21; 95% CI, 0.07-0.55) and miliary disease (aOR, 0.19; 95% CI, 0.01-0.96) were associated with lower odds of INH-monoresistant TB. Among 1,116 patients with pulmonary TB, the median time to sputum culture conversion was 30 days (interquartile range, 13-58). The rate of culture conversion was similar among patients with and without INH monoresistance (adjusted cause-specific hazard ratio, 1.15; 95% CI, 0.95-1.40). INH-monoresistant TB was not significantly associated with poor TB treatment outcomes (aOR, 1.61; 95% CI, 0.67-3.70) or mortality during TB treatment (aOR, 1.72; 95% CI, 0.58-4.94). CONCLUSIONS: Our findings suggest that compared with drug-susceptible TB, patients in Georgia with INH-monoresistant TB have a similar response to TB treatment including culture conversion rate, final TB treatment outcome, and all-cause mortality.
Authors: R S Wallis; M Phillips; J L Johnson; L Teixeira; L M Rocha; E Maciel; L Rose; C Wells; M Palaci; R Dietze; K Eisenach; J J Ellner Journal: Antimicrob Agents Chemother Date: 2001-04 Impact factor: 5.191
Authors: Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191
Authors: Medea Gegia; Nicholas Winters; Andrea Benedetti; Dick van Soolingen; Dick Menzies Journal: Lancet Infect Dis Date: 2016-11-17 Impact factor: 25.071
Authors: Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman Journal: PLoS Med Date: 2009-09-15 Impact factor: 11.069
Authors: Marcos C Schechter; Destani Bizune; Michelle Kagei; Mamuka Machaidze; David P Holland; Alawode Oladele; Yun F Wang; Paulina A Rebolledo; Susan M Ray; Russell R Kempker Journal: Clin Infect Dis Date: 2017-11-13 Impact factor: 9.079
Authors: Argita D Salindri; Sara C Auld; Marcos C Schechter; Neel R Gandhi; Matthew J Magee Journal: Ann Epidemiol Date: 2019-02-27 Impact factor: 3.797
Authors: Claire J Calderwood; James P Wilson; Katherine L Fielding; Rebecca C Harris; Aaron S Karat; Raoul Mansukhani; Jane Falconer; Malin Bergstrom; Sarah M Johnson; Nicky McCreesh; Edward J M Monk; Jasantha Odayar; Peter J Scott; Sarah A Stokes; Hannah Theodorou; David A J Moore Journal: PLoS Med Date: 2021-04-26 Impact factor: 11.069